ABBOTT PARK, Ill. – Abbott’s FreeStyle Libre Pro continuous glucose monitor has been approved by the U.S. Food and Drug Administration. “This novel technology provides a solution to the ongoing challenge of the need for complete and dependable glucose data,” said Jared Watkin, Abbott senior vice president of diabetes care, in a statement. A healthcare professional applies the sensor on the patient, where it remains for up to 14 days, requiring no patient interaction with the device or the need for fingerstick blood draws. The sensor continuously measures glucose and records levels every 15 minutes. After 14 days, the patient returns to the healthcare professional, who downloads and reads the results. The system has had CE Mark clearance in Europe since 2014.
You are here: / / Abbott receives FDA clearance for continuous glucose monitor